AS04 Clinical Decision Support Systems/Advisors

49 - REAL-WORLD USE OF IQCAST HYPOGLYCEMIA PREDICTION FEATURE IN THE GUARDIAN™ CONNECT SYSTEM AND ITS IMPACT ON CLINICAL OUTCOMES

Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Session Name
CLINICAL DECISION SUPPORT SYSTEMS/ADVISORS

Abstract

Background and Aims

Guardian™ Connect CGM system users can track the likelihood of experiencing low glucose episodes within a predictive window of 1 to 4 hours, using the IQCast feature in the Sugar.IQ™ diabetes assistant mobile application. The feature also notifies users of an impending low glucose episode. The frequency of low glucose episodes before and during four consecutive months of IQCast use were analyzed longitudinally.

Methods

Deidentified data from 259 individuals living with diabetes and who used the Sugar.IQ™ diabetes assistant prior to the introduction of the IQCast feature were selected for analysis. The mean (±SD) frequency of hypoglycemic (<70mg/dL) episodes was compared before IQCast use (15,639 days of data) and every month thereafter for four months (within-subjects ANOVA test, p<0.005 considered significant).

Results

Notifications of a predicted low glucose episode averaged 3.7/day. The overall and nighttime episodes/month observed for the 4 months before IQCast use was 17.8 (±16.2) and 5.1 (±5.9), respectively. For each month afterward, the frequency was 12.3 (±13.4), 12.0 (±12.9), 12.5 (±13.0) and 12.3 (±14.0) episodes/month and 3.5 (±4.4), 3.5 (±5.0), 3.6 (±4.5) and 3.4 (±5.7) episodes/month, respectively. Compared to the period before IQCast use, the frequency of hypoglycemic episodes post-use was significantly reduced (F[258,4]=15.63, p<0.001). This lowered frequency was maintained across the four-month period of IQCast use (F[258,3]=0.04, p=0.9867).

Conclusions

Results from this analysis demonstrate that using the Guardian™ Connect IQCast technology can result in a 31% decrease in the overall and nighttime hypoglycemic episode frequency.

Hide